HOUSTON, Aug. 23, 2012 Scientists at the University of Houston (UH) have discovered what may possibly be a key ingredient in the fight against Parkinson's disease.
Affecting more than 500,000 people in the U.S., Parkinson's disease is a degenerative disorder of the central nervous system marked by a loss of certain nerve cells in the brain, causing a lack of dopamine. These dopamine-producing neurons are in a section of the midbrain that regulates body control and movement. In a study recently published in the Proceedings of the National Academy of Sciences (PNAS), researchers from the UH Center for Nuclear Receptors and Cell Signaling (CNRCS) demonstrated that the nuclear receptor liver X receptor beta (LXRbeta) may play a role in the prevention and treatment of this progressive neurodegenerative disease.
"LXRbeta performs an important function in the development of the central nervous system, and our work indicates that the presence of LXRbeta promotes the survival of dopaminergic neurons, which are the main source of dopamine in the central nervous system," said CNRCS director and professor Jan-ke Gustafsson, whose lab discovered LXRbeta in 1995. "The receptor continues to show promise as a potential therapeutic target for this disease, as well as other neurological disorders."
To better understand the relationship between LXRbeta and Parkinson's disease, the team worked with a potent neurotoxin, called MPTP, a contaminant found in street drugs that caused Parkinson's in people who consumed these drugs. In lab settings, MPTP is used in murine models to simulate the disease and to study its pathology and possible treatments.
The researchers found that the absence of LXRbeta increased the harmful effects of MPTP on dopamine-producing neurons. Additionally, they found that using a drug that activates LXRbeta receptors prevented the destructive effects of MPTP and, therefore, may offer protection against the ne
'/>"/>
| Contact: Lisa Merkl lkmerkl@uh.edu 713-743-8192 University of Houston Source:Eurekalert |
Related biology news :
1. AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board
2. UofL research holds promise of therapeutic approach for gum disease
3. Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia
4. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
5. 2 Cell Transplantation studies impact dental stem cell research for therapeutic purposes
6. Understanding the RNAi Reagents Market Overlap with Drug Discovery and Therapeutic Development is Critical for Pharmaceutical Leaders
7. Magical state of embryonic stem cells may help overcome hurdles to therapeutics
8. New therapeutic target for prostate cancer identified
9. Cell research opens new avenues in combating neurodegenerative diseases
 |
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |